A second article in a series of four planned has just been published. It is about the health economics of treatment discontinuation. Led by Giovany Orozco-Leal the article can be…
It is over a decade ago now but I still recall vividly when, at the first meeting of what would become the aHUS alliance in 2013, the representative from Italy…
Stopping aHUS treatment when no longer needed is a big decision for patients. Global Action put the patients research agenda question to our expert. Can a complement inhibitor be stopped…
For aHUS patients stopping eculizumab (or even Ravulizumab) treatment is an important but emotive issue. Having had the treatment when seriously ill and then recovered, no one wants to go…
This is a plain language summary of the final article to be published about Stopping Eculizumab Treatment Safely Clinical Trial. The aim of the Stopping Eculizumab Treatment Safely atypical haemolytic…
From start to finish it’s been a busy year in the global ‘aHUS space’ yet before we say hello to 2026 issued our December 2025 edition of The aHUS Global…
Keeping track of medical advancements in the rare disease space is challenging, but for those interested in atypical HUS the aHUS Alliance Global Action team 'rounds up' new publications every…
What is it like from an aHUS patients' perspective to decide to withdraw from complement inhibitor treatment? Much is published about stopping complement inhibitor treatment but not from a patients…